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Deprescribing admission medication at a UK teaching hospital; a 1 
report on quantity and nature of activity 2 
Introduction 3 
Prescribing of a medication is informed by numerous factors including the diagnosis, general health and psycho-4 
social circumstances of the patient[1]. As these factors are not static; monitoring is required to ensure the 5 
prescribing does not result in a potentially inappropriate medicine (PIM). PIMs are those which are believed to 6 
afford more risks than benefits and are a pre-disposition to harms including adverse drug events, disability and 7 
mortality[2]. A multi-centre prospective analysis of older people’s admission medication reported PIM 8 
prevalence ranging from 34.7% to 77.3% across six European university teaching hospitals[3].  9 
The term ‘deprescribing’ has been defined as the “systematic process of identifying and discontinuing drugs in 10 
instances in which existing or potential harms outweigh existing or potential benefits…”[4]. Accordingly, 11 
deprescribing a medication may be in response to an adverse clinical trigger (reactive) or an attempt to reconcile 12 
risks of maintaining versus discontinuing (proactive)[5]. 13 
While the number of studies investigating clinically significant outcomes associated with deprescribing are 14 
limited, deprescribing appears safe and has been associated with positive effects on mortality and falls in certain 15 
circumstances[6]. Central to ensuring that deprescribing is safe and effective is an accurate medication history 16 
and provision for adequate physiological monitoring to observe response to medication withdrawal[4]. Given 17 
these requirements, an admission to hospital where a medication history is routinely undertaken and 18 
physiological parameters are routinely monitored, may provide an appropriate opportunity for a deprescribing 19 
intervention. However, deprescribing practice in hospital is poorly understood and there is a need identify the 20 
extent to which it currently occurs[7]. 21 
Aim of the study 22 
To quantify and describe the nature of admission medication deprescribing practice in a large UK teaching 23 
hospital. 24 
Ethics approval 25 
The study was confirmed as a service evaluation by the University of East Anglia Faculty of Medicine and 26 
Health Sciences Research Ethics Committee (Reference: 2016/2017 - 52 SE). 27 
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Method 28 
A retrospective analysis of all admission medications prescribed and discontinued at a large UK teaching 29 
hospital was undertaken over four weeks in February 2017. Data were extracted from the hospital’s electronic 30 
prescribing (e-prescribing) system for all wards and specialities except the Emergency Department and Intensive 31 
Care Unit as e-prescribing was not implemented in these areas. Prescriptions newly initiated during the 32 
admission and medication recorded as temporarily suspended were excluded because the study was designed to 33 
capture the extent to which admission medicines are deprescribed.  34 
Patient sex and age, medication name and the e-prescribing reason for medication discontinuation (selected by 35 
the prescriber from a list of 20 pre-defined reasons on the e-prescribing system, provided in Figure 1) were 36 
analysed. 37 
Not all medications recorded as discontinued on the e-prescribing system are ‘deprescribed’, such as those 38 
assigned the e-prescribing reason ‘Incorrect prescription’ or ‘Changed to when required’. Accordingly, a team 39 
of clinical pharmacists and consultant physicians classified the e-prescribing reasons into ‘not considered 40 
deprescribing’ (excluded from analysis) and ‘potentially deprescribing’ as described in Figure 1.  41 
A sample of 200 medication discontinuations assigned a ‘potentially deprescribing’ e-prescribing reason were 42 
further analysed by reviewing medical records to confirm or refute deprescribing activity and categorise the 43 
activity into proactive or reactive. This sample size provides a 95% confidence interval of 3.0% around the 44 
estimate of the quantity of deprescribing. As there are no estimates of deprescribing prevalence in usual hospital 45 
care, the estimate is based on a UK deprescribing intervention trial reporting 8.5% of admission medicines 46 
deprescribed[8]. Accepting this will be lower in the absence of an intervention, we estimated a maximum of 47 
5.0% admission medicines likely to be deprescribed.  48 
The majority of e-prescribing reasons are unambiguous such as “Acute kidney injury”. However, the reason “No 49 
longer clinically necessary” was deemed ambiguous by the local clinical team as in their experience this was 50 
often selected by prescribers when a suitable reason could not be identified. Medication discontinuations not 51 
assigned an e-prescribing reason were also considered ambiguous. Accordingly, sampling of 200 medication 52 
discontinuations was stratified, with a smaller number of discontinuations assigned unambiguous reasons (one-53 
sixth of the total or 100% if three or less occurrences) sampled. Medication discontinuations assigned the 54 
ambiguous reason and where no reason was given were evenly sampled for the remaining reviews. Figure 2 55 
provides the numbers sampled across the e-prescribing reason strata. 56 
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Informed by the existing literature[5], academics, senior hospital clinicians, patients and carers, the following 57 
definitions were developed and used to categorise deprescribing behaviour: 58 
 Reactive deprescribing: discontinuing a medicine in response to an adverse clinical trigger 59 
 Proactive deprescribing: discontinuing a medicine if future gains are unlikely to outweigh future harms 60 
One clinical pharmacist extracted the prescriber’s rationale for medication discontinuation verbatim from 61 
medical records. Each discontinuation was independently categorised by a clinical pharmacist and consultant 62 
physician into proactive, reactive or not deprescribing. Inter-rater reliability was assessed using Cohen’s Kappa, 63 
with k=0.6-0.8 considered good and k>0.8 excellent[9]. Disagreements were resolved through reviewer 64 
discussion and referral to a third reviewer if necessary.  65 
Data from the stratified sample of 200 reviews were extrapolated to the total ‘potentially deprescribing’ 66 
discontinuations through multiplying sample deprescribing prevalence within each reason statement by the total 67 
number of discontinuations within each reason statement. These were summed to estimate the total proportion 68 
and 95% confidence interval (95% CI) of admission medicines deprescribed in hospital and the proportion (95% 69 
CI) which were reactive and proactive.  70 
Results 71 
From 24,552 admission medicines prescribed for 2,309 patients, 977 discontinuations were recorded across 415 72 
patients, of which 682 (69.8%) were ‘potentially deprescribing’ according to the e-prescribing reason. Females 73 
constituted 228 (54.9%) patients and the median (IQ) age was 79.0 (66.0, 86.0) years. Figure 1 provides the e-74 
prescribing reasons for discontinuation retained and excluded from the analysis according to whether they were 75 
potentially consistent with deprescribing as defined in the introduction. 76 
 77 
Fig.1 E-prescribing recorded medication discontinuations excluded and retained from analysis according to the 78 
e-prescribing reason selected by the prescriber. 79 
 80 
Stratified sampling and, proactive and reactive categorisation of the 200 medication discontinuations further 81 
analysed by reviewing the medical records are described in Figure 2. Unambiguous e-prescribing reasons 82 
accounted for 21.0% of the sample. The remaining 158 (79.0%) records were evenly sampled from the 83 
ambiguous e-prescribing reason “No longer clinically necessary” and from no e-prescribing reason recorded. 84 
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One-hundred and forty-three (71.5%) discontinuations reviewed were not consistent with the definitions for 85 
proactive or reactive deprescribing for the reasons; end of life care, treatment escalation or the medication being 86 
stopped in error. For a further 13 (6.5%), insufficient information was available for categorisation. The 87 
remaining 44 (22.0%) confirmed deprescribing activities were categorised into 7 (15.9%) proactive and 37 88 
(84.1%) reactive. Agreement between reviewers categorising deprescribing activity was excellent (κ=0.872, 89 
p<0.01). 90 
Reasons provided in the medical records for medication deprescribed reactively were; side effect (21 (56.8%)), 91 
acute kidney injury (8 (21.6%)), treatment failure (5 (13.5%)), swallowing difficulty (1 (2.7%)), allergic 92 
reaction (1 (2.7%)) and interaction with other treatment (1 (2.7%)). All proactive deprescribing was in response 93 
to resolution of the indication for which the medication was first prescribed as reported by the patient or 94 
physiological parameters. 95 
Extrapolation of the 200 stratified sample data to the 682 total discontinuations yielded 22.01% (19.0%-25.2%) 96 
consistent with deprescribing, of which 19.2% (12.9%-25.5%) are proactive and 80.8% (75.5%-87.1%) are 97 
reactive. This corresponds to 0.6% (0.5%-0.7%) of all admission medications prescribed being deprescribed. 98 
 99 
Fig. 2 Categorisation of a stratified sample of 200 recorded medication discontinuations and extrapolation to the 100 
total 682 recorded medication discontinuations potentially considered deprescribing (according to the e-101 
prescribing reason provided) 102 
*Medication discontinued however rationale provided in the medical records was not consistent with proactive 103 
or reactive deprescribing e.g. medication discontinued due to end of life diagnosis 104 
**Medication re-prescribed at the point of medical records review. Medication discontinuation recorded for an 105 
erroneous reason such as discontinued in error and immediately re-prescribed. 106 
Discussion 107 
Very limited deprescribing activity was identified in this one UK hospital. Dominance of reactive deprescribing 108 
suggests that prescribers require the presence of a clinical trigger such as an adverse drug event to prompt 109 
deprescribing. The low levels of proactive deprescribing are in accordance with primary care research which 110 
reports that practitioners find it challenging to evaluate potential risks and harms associated with medication to 111 
inform deprescribing[5]. It is conceivable that hospital practitioners may also find this challenging. Findings 112 
5 
 
from the present study endorse this hypothesis, as the observed proactive deprescribing was only in cases with 113 
documented evidence of no clinical benefit thus only potential for harm. There was therefore no proactive 114 
deprescribing identified as a result from a complex evaluation of risks and benefits.  115 
Accepting the limitations of not assessing the prevalence of PIMs in the present study, given that the 116 
deprescribing prevalence was 0.6% it can be concluded that the vast majority of PIMs are unlikely to be being 117 
discontinued during the hospital admissions. There may therefore be scope for increasing proactive 118 
deprescribing activity in hospital. However, the extent to which this is feasible and acceptable is as yet 119 
unknown. A future study should therefore seek to explain low proactive deprescribing activity in hospital and 120 
explore the support required for prescribers and patients to increase this activity. 121 
There are two key limitations to this study. Firstly, data is limited to one UK hospital, restricting the 122 
generalisability of findings. More widespread analysis of deprescribing in hospital is warranted for comparison. 123 
Secondly, the large proportion of sampled medication discontinuations that were not deprescribing incorporates 124 
a degree of ambiguity around the final proportions. Random, stratified sampling and extrapolation of almost a 125 
third of the total medication discontinuations was employed to mitigate this limitation. 126 
Conclusion 127 
The one teaching hospital under investigation was found to be undertaking very limited deprescribing activity, 128 
which was dominated by reactive behaviour. Where significant deprescribing is identified this could be explored 129 
to understand the reasons underpinning the behaviour. 130 
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E-prescribing discontinued 
medications recorded n=977 
Not considered deprescribing (n=295) 
• Palliative (110) 
• Incorrect prescription (n=66) 
• Enablement policy (n=54) 
• Non-formulary drug (n=27) 
• Duplicate (n=18) 
• Changed to when required (n=3) 
• Changed to regular (n=9) 
• Course complete (n=8) 
 
Medication discontinuations 
not considered deprescribing 
according to the e-prescribing 
reason were removed from 
further analyses 
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 185 
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 189 
 190 
Potentially deprescribing (n=682) 
• No longer clinically necessary (n=328) 
• No reason documented (n=138) 
• Route no longer appropriate (n=87) 
• Formulation no longer appropriate (n=64) 
• Interaction with other treatment (n=20) 
• Biochemistry deranged (n=14) 
• Patient refusing to take (n=7) 
• Renal impairment (n=7) 
• Haemodynamically unstable (n=6) 
• Suspected toxicity/high levels (n=4) 
• Blood dyscrasia (n=3) 
• Acute kidney injury. Not to be restarted (n=2) 
• Drowsy (n=2) 
 
Stratified sample of 200 medication 
discontinuations considered to be potentially 
deprescribing analysed by reviewing medical 
records to establish whether deprescribing, and 
categorise deprescribing behaviour as reactive 
or proactive (see Figure 2). 
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Unambiguous e-prescribing reasons sampled (n=42 
(21.0%)) 
 Acute kidney injury. Not to be restarted (n=2) 
 Biochemistry deranged (n=2) 
 Blood dyscrasia (n=3) 
 Drowsy (n=2) 
 Formulation no longer appropriate (n=11) 
 Haemodynamically unstable (n=1) 
 Interaction with other treatment (n=3) 
 Patient refusing to take (n=1) 
 Renal impairment (n=1) 
 Route no longer appropriate (n=15) 
 Suspected toxicity/high levels (n=1) 
Ambiguous e-prescribing reasons or no reason given 
sampled (n=158.0, 79.0%)) 
 No longer clinically necessary (n=79) 
 No reason documented (n=79) 
 
Confirmed 
deprescribing (n=11, 
(26.2%)) 
 Reactive (n=11, 
(100%)) 
Not deprescribing (n=31, 
(73.8%)) 
 Neither* (n=9, 
(29.0%)) 
 Not discontinued** 
(n=21, (67.7%)) 
 Insufficient 
information to 
categorise (n=1, 
(3.2%)) 
Not deprescribing 
(n=125, (79.1%)) 
 Neither* (n=41, 
(32.8%)) 
 Not discontinued** 
(n=72, (57.6%)) 
 Insufficient 
information to 
categorise (n=12, 
(9.6%)) 
Confirmed 
deprescribing (n=33, 
(20.9%)) 
 Reactive (n=26, 
(78.8%)) 
 Proactive (n=7, 
(21.2%)) 
Not deprescribing (n=531) 
 Neither* (n=155, (29.2%)) 
 Not discontinued* (n=331, 
(62.3%)) 
 Insufficient information available 
to categorise (n=45, (8.5%)) 
Deprescribing (n=151) 
 Proactive (n=29, 
(19.2%)) 
 Reactive (n=122, 
(80.8%)) 
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Analysis of 200 medication discontinuation by medical records review 
